Sphera Funds Management LTD. Grows Stock Position in Immatics (NASDAQ:IMTX)

Sphera Funds Management LTD. boosted its position in shares of Immatics (NASDAQ:IMTX - Free Report) by 27.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 921,111 shares of the company's stock after acquiring an additional 200,000 shares during the period. Immatics comprises 1.2% of Sphera Funds Management LTD.'s investment portfolio, making the stock its 28th biggest holding. Sphera Funds Management LTD. owned about 0.77% of Immatics worth $6,549,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Bank of America Corp DE grew its stake in shares of Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock worth $25,000 after purchasing an additional 2,231 shares in the last quarter. Virtus ETF Advisers LLC boosted its position in shares of Immatics by 34.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after acquiring an additional 2,479 shares in the last quarter. Guggenheim Capital LLC acquired a new position in shares of Immatics during the 4th quarter worth about $101,000. Forefront Analytics LLC increased its holdings in shares of Immatics by 42.3% in the 4th quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock valued at $113,000 after acquiring an additional 4,731 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in shares of Immatics during the 4th quarter worth about $130,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Price Performance

Shares of IMTX traded down $0.36 during midday trading on Wednesday, reaching $5.04. 274,960 shares of the stock were exchanged, compared to its average volume of 657,530. The company has a market capitalization of $612.61 million, a price-to-earnings ratio of -7.63 and a beta of 0.87. Immatics has a twelve month low of $3.30 and a twelve month high of $13.77. The business's 50-day moving average price is $4.51 and its 200 day moving average price is $5.79.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The business had revenue of $20.12 million during the quarter, compared to the consensus estimate of $14.92 million. As a group, equities research analysts expect that Immatics will post -0.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immatics in a report on Tuesday, April 1st.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.